Cohen & Steers, Inc. (CNS) — Fair Value Analysis
Base-case fair value (P50): $65.88 · Current price: $72.30 · Verdict: Fairly Valued
The Verdict on CNS
COHEN & STEERS INC (CNS) is currently deemed Fairly Valued based on our comprehensive Monte Carlo simulations, despite trading at $72.30. Our analysis suggests a median fair value (P50) of $65.88, implying an -8.9% gap relative to its current market price. This verdict indicates that CNS's present valuation closely reflects its intrinsic worth as projected across thousands of forward-looking scenarios. The minimal -8.9% difference underscores a balanced risk-reward profile at the $72.30 level, suggesting limited immediate outperformance potential from a valuation perspective. Investors should interpret the Fairly Valued assessment as CNS trading near its theoretical equilibrium based on current inputs.
How CNS stacks up against peers
Our quality tier assessment for CNS is currently unrated, meaning its operational and financial health against sector peers has not been fully benchmarked. With no specific sector identified, direct peer comparisons are not applicable. However, the Fairly Valued verdict remains robust, derived solely from extensive Monte Carlo simulations performed on CNS's individual financial data. The absence of a quality rating doesn't negate the fundamental valuation insight provided by the $65.88 median fair value relative to the $72.30, highlighting that while the -8.9% valuation gap suggests balance, deeper fundamental context on its competitive standing would be additive.
What this means for investors
Investors evaluating COHEN & STEERS INC should note that its Fairly Valued status, with a median fair value of $65.88 against a current market price of $72.30, suggests equilibrium rather than a compelling deep value or extreme overvaluation. The -8.9% deviation implies a significant upward re-rating based solely on valuation models is unlikely short-term, though a steep downside scenario is also not heavily weighted by current intrinsic value projections. While $72.30 aligns closely with $65.88, understanding the full range of potential outcomes is crucial. For a deeper understanding of price movements, including both bull and bear case outcomes from our rigorous Monte Carlo models, a free FairCurve account provides access to the full probability distribution. Add CNS to your FairCurve watchlist to see the full bear/bull distribution and track CNS's fair value as new fundamentals are released.
Frequently Asked Questions
Is CNS overvalued or undervalued right now?
Based on our Monte Carlo simulations, CNS is currently deemed Fairly Valued. Its median fair value (P50) of $65.88 is closely aligned with its current market price of $72.30, suggesting it's trading near its intrinsic worth.
What is the bear case and bull case for CNS?
To understand the full spectrum of potential outcomes for CNS, including the bear case (P10) and bull case (P90) price targets, along with the probability of upside, sign up for a free FairCurve account. This data is part of the comprehensive Monte Carlo distribution available to subscribers.
How does FairCurve calculate CNS's fair value?
FairCurve calculates CNS's fair value through robust Monte Carlo simulations, running thousands of forward-looking financial scenarios. This process generates a probability distribution of potential future values to determine a median fair value.
How can I track CNS's fair value as it changes?
You can easily track CNS's fair value by adding it to your free FairCurve watchlist. This provides daily fair-value updates and instantly re-values the company whenever new earnings or fundamental data are released.